The criminal legal system in the United States—comprising police stations, courts, jails, prisons, halfway houses, and community supervision settings—hosts millions of individuals affected by substance use disorders. Yet, the clinical and economic complexities of delivering effective treatment in these heterogeneous and resource-constrained environments remain underexplored. Historically, incarcerated individuals have often faced abrupt discontinuation of substance use treatments upon entry, triggering untreated withdrawal syndromes and a cascade of adverse health outcomes, including a devastating spike in overdose risk post-release.

This new grant underpins the establishment of the Criminal-Legal Economic Analysis & Resource (CLEAR) Center, which will operate within the broader framework of the Justice Community Overdose Innovation Network (JCOIN-II), an initiative dedicated to developing empirically validated, system-wide solutions for substance use disorder care integrated into criminal justice settings. Since its launch in 2019, JCOIN has focused on bridging gaps between clinical research and real-world implementation in notoriously fragmented correctional environments, striving to initiate treatment from incarceration through community reintegration.

Dr. Sean Murphy, professor in the department of population health sciences at Weill Cornell Medicine and one of the CLEAR Center’s co-principal investigators, emphasized the transformative potential of rigorous economic analyses. “CLEAR’s mission is not only to identify which interventions offer the best health outcomes but also to elucidate their economic viability, equipping policymakers and administrators with actionable tools to optimize budget allocation amidst chronic fiscal restraints,” Dr. Murphy explained.

Co-leading the initiative, Dr. Kathryn McCollister, professor and interim chair of public health sciences at the University of Miami’s Miller School of Medicine, brings extensive expertise in health economics methodology. Together, they aim to generate nuanced cost-effectiveness evaluations across a spectrum of clinical trials targeting substance use disorders, providing critical insights into designing scalable, sustainable programs within criminal-legal settings.

The complexity of the U.S. criminal legal system arises from its disparate institutional components, each operating with distinct budgetary realities, staffing structures, and regulatory constraints. This fragmentation historically obstructs the consistent delivery of evidence-based treatments, which are critical given the heightened vulnerability to relapse and overdose that individuals face immediately following release from incarceration. Effective intervention strategies must therefore be comprehensive and seamlessly integrated throughout all system phases.

The CLEAR Center’s analytical framework will incorporate the development of sophisticated decision-support tools, including cost-benefit analyses and budget-impact models, to facilitate strategic planning by criminal justice administrators and treatment providers. Such instruments will enable stakeholders to evaluate financial implications in the context of clinical efficacy, allowing for optimized resource deployment to maximize population-level health benefits.

Moreover, the CLEAR team will provide ongoing consultation and technical assistance to JCOIN-II clinical trials, ensuring that economic endpoints are robustly embedded into study designs. This interdisciplinary approach supports the translation of trial outcomes into practical guidelines for large-scale implementation, addressing a critical gap between research evidence and criminal justice policy execution.

Drs. Murphy and McCollister bring a strong foundation in substance use disorder health economics through their leadership roles within CHERISH, a NIDA-funded center of excellence focused on intersectional epidemics of addiction, HIV, and hepatitis C. Their collaboration within CHERISH, which recently received a renewed five-year, $10.9 million grant, underscores their capacity to conduct rigorous, policy-relevant health economic research at the nexus of complex infectious diseases and substance use.

This latest funding signals a commitment to confronting not only the biomedical challenges of addiction in incarcerated populations but also the economic and systemic barriers that hinder effective care delivery. By quantifying the value of evidence-based interventions within the fiscal realities of criminal justice agencies, the CLEAR Center aspires to catalyze a paradigm shift in how substance use disorders are addressed in these high-need populations.

The ultimate goal is to achieve sustained health improvements by rapidly initiating treatment upon incarceration and ensuring continuity of care immediately upon release—critical junctures where the risk of overdose and mortality surges dramatically. Through rigorous economic evaluation, CLEAR’s outputs will provide the empirical foundation necessary for advocating investment in interventions that demonstrate clear cost-effectiveness and public health impact.

As the opioid epidemic and other substance use crises continue to devastate communities, this innovative fusion of health economics and justice system reform represents a pivotal step toward deploying limited resources more strategically. The integration of economic insights into clinical and policy decision-making holds promise for mitigating overdose deaths and improving long-term recovery outcomes for individuals entangled in the criminal legal system.

In summary, the CLEAR Center, fortified by this new NIDA grant, will pioneer the generation and dissemination of robust economic evidence on substance use disorder interventions tailored to the unique context of the U.S. criminal justice system. Its success will depend on delivering pragmatic, actionable analyses that align with both clinical efficacy and budgetary feasibility, thus empowering decision-makers to enact sustainable, impactful reforms in addiction treatment services.

Subject of Research: Health economics of substance use disorder treatments and overdose prevention strategies within the criminal legal system.

Article Title: Not provided.

News Publication Date: Not provided.

Web References:

• Weill Cornell Medicine Sean Murphy profile
• University of Miami Kathryn McCollister profile
• CHERISH Renewal News

References:

• Link to the JAMA Network Open article on inadequacy of interventions
• Link to The Lancet article on post-release overdose risk

Image Credits: Not provided.

Keywords: Substance abuse, Substance related disorders, Behavioral psychology, Health economics, Criminal justice system, Substance use disorder, Overdose prevention, Cost-effectiveness, Population health sciences

The centerpiece of this innovative effort is the Justice Community Overdose Innovation Network (JCOIN), an initiative begun by the NIH in 2019. JCOIN represents the first evidence-based framework for delivering medication-assisted treatment (MAT) to individuals with opioid use disorder while they are incarcerated—a critical step forward in addressing the opioid epidemic, which continues to ravage communities across the United States. JCOIN’s success is vital given the unique vulnerabilities and health disparities faced by incarcerated populations.

During the first phase of the Massachusetts JCOIN Hub, led by Elizabeth Evans, a professor and associate chair in community health education and health policy at UMass Amherst’s School of Public Health and Health Sciences, the research team partnered with seven correctional facilities spanning urban and rural settings. Their goal was to evaluate a pilot program offering medications for opioid use disorder (MOUD) within jail environments, while also monitoring the implementation processes, treatment outcomes, and economic costs. These findings emphasized both the effectiveness and challenges of jail-based interventions.

One of the stark findings from this study was that incarcerated individuals receiving MOUD showed significantly improved health outcomes compared to those who did not receive such treatment. However, a substantial hurdle emerged: many individuals discontinued their MOUD regimen after release, which diminishes the long-term efficacy of treatment programs started within jail facilities. This discontinuity in care has severe consequences, including heightened risks of relapse and overdose mortality during the critical reentry period.

Building on this insight, Evans’ new line of research will focus on developing strategies to enhance continuity of care after release. Specifically, this involves launching an intervention at four Massachusetts jails designed to support formerly incarcerated individuals in maintaining their MOUD therapy. A critical component of this work investigates barriers to access, with particular attention paid to the historical suspension or freezing of Medicaid coverage during incarceration.

Medicaid access has long been a barrier for incarcerated populations, impeding their ability to secure timely and effective treatment upon reentry into the community. Massachusetts has taken a pioneering step by securing federal approval through a Section 1115 waiver, which allows Medicaid benefits to activate up to 90 days before an individual’s release. This policy aims to facilitate uninterrupted healthcare access—including crucial substance use disorder treatments—bridging detention and community life.

The intervention developed by Evans and her team will rigorously evaluate whether this Medicaid waiver provision effectively increases healthcare access, improves health outcomes, and supports sustained MOUD engagement. Collaborators on this project include UMass Amherst’s Michal Horný, an expert in health policy and management, and Ekaterina “Kate” Pivovarova, who brings deep clinical expertise from her field of family medicine and community health at UMass Chan Medical School.

Massachusetts is serving as a critical testbed for these innovative correctional health initiatives. Should the approaches prove successful, they may offer scalable and adaptable models for other states grappling with similar opioid-related challenges within their criminal justice systems. The state’s existing pilot sites, including jails in Western Massachusetts and the Boston area, continue to function as vital research grounds.

A related NIH-funded project led by Pivovarova and Evans is designed to forge alliances between court systems and MOUD providers, seeking to redirect individuals with opioid use disorder towards treatment programs instead of incarceration. This approach recognizes the intersection between the legal system and public health imperatives and aims to circumvent cycles of recidivism and untreated addiction.

Moreover, Evans, alongside Dr. Alysse Wurcel from Boston Medical Center, will spearhead a new $4.7 million initiative focused on HIV prevention and treatment among incarcerated populations. This program was prompted by a recent HIV outbreak in a Boston-area jail and underscores the urgent need for integrated health interventions within correctional settings, where both infectious diseases and substance use disorders concurrently pose severe public health risks.

Correctional institutions are often overlooked healthcare access points; yet they offer strategic opportunities to deliver critical testing, prevention, and treatment services for both infectious diseases and substance use disorders. By embedding comprehensive health services within jails, these programs aim to turn correctional facilities into pivotal components of the broader public health infrastructure, reducing disparities and improving long-term community health outcomes.

With these comprehensive efforts, the University of Massachusetts Amherst and its partners are pushing boundaries in public health research aimed at vulnerable populations. This multifaceted approach leverages policy reform, healthcare innovation, and cross-sector collaboration to address systemic issues that have long perpetuated health disparities among incarcerated individuals. In doing so, the research sets a precedent for evidence-driven models that could reshape addiction and infectious disease treatment paradigms within the criminal justice context nationwide.

These initiatives underscore an urgent, science-based response to the intertwined epidemics of opioid addiction and HIV within justice-involved populations. Their success could pave the way for transformative public health policies that not only improve individual outcomes but also generate broader societal benefits by reducing overdose deaths, curbing infectious disease transmission, and improving pathways to recovery and rehabilitation.

Subject of Research:
Public health interventions addressing opioid use disorder and HIV among incarcerated populations, including jail-based medication-assisted treatment and Medicaid-linked care continuity.

Article Title:
Massachusetts Research Pioneers Innovative Jail-Based Treatments for Opioid Use Disorder and HIV Amidst the National Epidemics

News Publication Date:
Not specified

Web References:
https://www.umass.edu/public-health-sciences/about/directory/elizabeth-evans
https://www.umass.edu/public-health-sciences/academics
https://www.jcoinctc.org/
https://reporter.nih.gov/search/EHZAUseXuEmZozB9wq6zyw/project-details/11261921

Image Credits:
UMass Amherst